DAY ONE
Wednesday 9th April, 2025
7:30 am Check In & Light Breakfast
8:20 am Chair’s Opening Remarks
Shaping the Future of Precision Oncology with Genomic Initiatives & Liquid Biopsy to Tackle Hard-to-Treat Cancers for Unmet Patient Need
8:30 am Advancing Faster Diagnosis of Pancreatic & Biliary Tract Cancers with Liquid Biopsies to Improve Clinical Impact & Optimise Patient Treatment Outcomes
Synopsis
- Pancreatic and Bile Duct cancers can be associated with protracted diagnostic pathways
- Both diseases are associated with high levels of ctDNA detection
- Showcasing the potential for a liquid biopsy enhanced diagnostic pathway for faster, safer, accurate diagnosis of these challenging cancers
8:50 am Session Reserved for Foundation Medicine
Synopsis
Presentation Details to be Announced
9:20 am Using the National Genomic Research Library Clinico-Genomic Data for Biomarker Discovery – Genomics England Use Cases
Synopsis
- National Genomic Research Library holds one of the largest collections of whole genome sequencing (WGS) data linked to clinical records across 200+ rare disease disorders and over 16 cancer types for consented participants
- NHS Genomics Medicine Service has commissioned WGS as standard of care for a number of indications, enabling future growth of the dataset
- Genomics England unique model, enabling use of consented data for clinical and research applications, enables true translation of research back to the clinic, driving the future of precision medicine in UK and around the world
9:40 am Session Reserved for Guardant Health
Synopsis
Presentation Details to be Announced
10:10 am Morning Break & Structured Networking
Synopsis
An opportunity to network, discuss and collaborate with like-minded leaders of the biomarker and CDx community
Bolstering the Equitable Access of Precision Therapies Through Innovative Trials & Sequencing Initiatives to Reduce Treatment Disparities & Improve the Standard of Care for All Patients
11:10 am Developing Blood-Based Biomarkers to Stratify Alzheimer’s Patients & Deploy Improved Neurodegenerative Treatments using Exploratory Biomarker Panels
Synopsis
- Using blood based biomarker to understand the pathological processes in the brain
- Validation of assays making them fit for the intended purpose
- Understanding the ability of staging patients based on biomarkers and not imaging or scoring tests
- Establishing multi-institutional and cross-sector collaboration to accelerate the clinical adoption of blood-based biomarkers for Alzheimer’s
11:30 am Discover How SOPHiA GENETICS is Empowering Pharma Companies to Advance Precision Medicine with Next-Generation Genomics Solutions, Improving Patient Access to Innovative Therapies
Synopsis
- Learn how to unlock the potential of SOPHiA DDM™ to optimise late-stage clinical development by designing and deploying genomics solutions at scale
- Gain insights into the regulatory pathway of the SOPHiA DDM™ Platform and its validation path for broadening access to precision therapies
- Understand SOPHiA GENETICS’ market-leading lab footprint and ability to truly democratise genomics
- Hear how SOPHiA GENETICS and AstraZeneca are joining forces to shape healthcare’s future by standardising and decentralising a best-in-class liquid biopsy assay on a global scale
12:00 pm Addressing Testing Disparities to Reduce Health Inequalities & Reinforce Equitable Patient Access
Synopsis
- What are the best practices to engage with diverse patient communities and ensure successful enrolment of under-represented groups?
- Adopting inclusive recruitment strategies that overcome biases in clinical trials and improve patient access to testing and monitoring
- What is the role of technology in overcoming healthcare access barriers for marginalised populations in the context of diagnostic testing?
12:30 pm Session Reserved for Illumina
Synopsis
Presentation Details to be Announced
1:00 pm Lunch Break & Networking
TRACK A: Biomarker Discovery & Clinical Development
Leveraging Advanced Computing & AI to Enhance Predictive Accuracy & Bolster Scalable & More Cost-Effective Biomarker Development
2:00 pm Paving a Pathway Towards Computational & Digital Pathology for Enhanced Interpretation & More Targeted Intervention
Synopsis
- What is the role of Pharma in the adoption of computational pathology?
- Where has co-development been leveraged to create integrated digital pathology platforms?
- Navigating commercial implications regarding the need for computational algorithms for treatment identification, scanner deployment, site distribution, and expected market penetration
2:20 pm Session Reserved for Diagnexia
Synopsis
Presentation Details to be Announced
2:50 pm From Real-World Patient Data to Precision Therapeutics: A Case Study in Applying AI-Enabled Patient Endotyping & Multiple Omics Modalities to Diabetic Nephropathy
Synopsis
- What are the challenges of assembling real world patient cohorts and datasets to generate relevant multi-omics data?
- Identifying patient subpopulations using machine learning in a way that remains meaningful to physicians
- How AI-enabled techniques can enable patient stratifying biomarker models with high predictivity
- What are the key hurdles to determining drug targets that will be most relevant to specific patient subpopulations?
3:10 pm Session Reserved for Bio-Techne
Synopsis
Presentation Details to be Announced
TRACK B: CDx Development & Commercialisation
Improving Access with Novel CDx & Real-World Data for Effective Care Pathways
2:00 pm An In Vitro Diagnostic Test for Dose Maintenance Setting in Patients Treated with Concizumab
Synopsis
- Concizumab is an anti TFPI monoclonal antibody intended for all haemophilia A and B types
- Treatment with concizumab require dose maintenance setting based on concizumab exposure levels 4 weeks after treatment initiation using an IVD
- A ConcizuTrace ELISA test access solution provides a complete service portal for CDx test ordering and CDx test result provision
2:20 pm From Liquid Biopsy to Dynamic Monitoring: ctDNA Empowering Cancer Treatment Optimisation
Synopsis
- Explaining the unique value of liquid biopsy in patient selection and therapeutic monitoring
- Showcasing clinical applications of Burning Rock‘s CanCatchTM for MRD-guided treatment adjustments
- Sharing real-world examples of ctDNA monitoring in evaluating therapeutic response and enabling personalised treatment strategies
- Presenting case studies, including sensitive urinary cfDNA assays for bladder cancer detection and monitoring
2:50 pm Genomics & Diagnostic Data for Disease Population Sequencing Using Secondary Health Data
Synopsis
- Purpose-built repositories for real-world data use
- Linking between registries for granular analysis of health data
- Use cases of integration of genomic and diagnostics into RWE study designs
3:10 pm Developing Biomarker Assays With Commercialisation in Mind
Synopsis
- Many therapeutics require co-development of a diagnostic test to select and enrich for biomarker-positive patient populations
- Discovery’s approach of utilising laboratory-developed tests to support early phase development permits rapid development and deployment to support patient management
- We will present a brief overview of the Discovery process with an emphasis on regulatory compliance and commercial foresight if a regulated CDx is required
3:40 pm Afternoon Networking Break
Synopsis
An opportunity to network, discuss and collaborate with like-minded leaders
Shaping the Future of Patient Selection & Monitoring to Inform Treatment Regimes for Best-in-Class Cancer Therapies
4:10 pm Roundtable Discussion: Advancing Patient Selection & Monitoring Across Therapeutics Modalities in Precision Oncology for Improved Clinical Outcomes
Synopsis
- How can you optimise the use of tumour and blood-based biomarkers for dynamic patient selection and treatment monitoring in oncology clinical trials? How does this vary between therapeutic modality?
- Addressing the challenge of biomarker heterogeneity within solid tumors and its impact on accurate patient stratification for oncology therapies
- Why is biomarker assay standardisation critical for clinical adoption, and what collaborative efforts between biopharma, diagnostics, and regulatory agencies can streamline this process?
4:30 pm Session Reserved for Panakeia
Synopsis
Presentation Details to be Announced
4:40 pm Strategic Development of a Selection Test for Targeted Therapy: A Case Study
Synopsis
- Test development process: selection of appropriate tool and platform; analytical validation
- Determination of positive cut-off and its iterative refinement to adapt to emerging data throughout development
- Bridging the test across development phases to ensure consistency and compliance with trial and regulatory requirements
Strengthening Co-Development Partnerships for Rapid Market Access to Maximise Therapeutic Reach
4:10 pm Panel Discussion: Advancing Partnerships within Novel & Digital Technologies to Ensure Compliant, Scalable Solutions for Global Precision Medicine Applications
Synopsis
- What is the role of strategic partnerships in effectively utilising advanced computing tools in clinical and healthcare settings?
- How can we ensure the integration of advanced technologies in compliance with global regulatory standards for precision medicine applications?
- What does the reimbursement of digital and novel technological infrastructure entail?
4:40 pm A Match Made in Oncology: Optimising Co-Development Partnerships for the Accelerated Approval of Precision Oncology Therapies
Synopsis
- How soon should biopharma and diagnostic providers initiate collaboration to optimise the development of companion diagnostics for precision oncology?
- How and when to initiate performance studies to collect and establish data for the CDx
- What are the key challenges in scaling up co-development partnerships for precision oncology therapies, and how can these challenges be mitigated?
- What is the impact and opportunity of dual-pharmaceutical alliances on the co-development of precision therapies?